ASCO: IMAB362 Can Lengthen Lives of Gastric Cancer Patients

Share this content:
ASCO: IMAB362 Can Lengthen Lives of Gastric Cancer Patients
ASCO: IMAB362 Can Lengthen Lives of Gastric Cancer Patients

MONDAY, June 6, 2016 (HealthDay News) -- A novel antibody that targets claudin 18.2 is helping some patients with advanced gastric cancer live longer, according to a study presented at the annual meeting of the American Society of Clinical Oncology (ASCO), held from June 3 to 7 in Chicago.

The phase II clinical trial, involving 161 patients, focused on the antibody IMAB362. The median survival of patients using the treatment plus standard chemotherapy was 13.2 months, compared with 8.4 months for those who received chemotherapy alone, the researchers reported.

The IMAB362 antibody employed in this new treatment targets the claudin 18.2 protein. The researchers found that study patients who had the highest levels of this protein in tumors prior to receiving the new treatment had an even longer median overall survival, at 16.7 months.

"Since claudin 18.2 is abundant in gastric tumors, we estimate that half of all patients with advanced gastric cancer may be candidates for this new treatment," lead researcher Salah-Eddin Al-Batran, M.D., of the Institute of Clinical Cancer Research at Nordwest Hospital in Frankfurt, Germany, said in an ASCO news release. In addition, "this unique target is not present in any healthy tissues except the lining of the stomach, thereby minimizing treatment side effects."

The research was funded by Ganymed Pharmaceuticals, the manufacturer of IMAB362.

Press Release
More Information

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions

More in Home

Higher Fish Intake Appears to Reduce RA Symptoms

Higher Fish Intake Appears to Reduce RA Symptoms

Researchers suggest most varieties of fish may play a role in controlling symptoms

Longer Survival for Midostaurin  Chemotherapy in AML With FLT3

Longer Survival for Midostaurin + Chemotherapy in AML ...

Prolonged overall, event-free survival for patients with acute myeloid leukemia, FLT3 mutation

HIV Testing Inadequate in Young Men Who Have Sex With Men

HIV Testing Inadequate in Young Men Who Have ...

Only 28 percent of young MSM have HIV testing, though they account for 83 percent of new diagnoses

is free, fast, and customized just for you!

Already a member?

Sign In Now »